Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BALRAJ SINGH and ANTHONY LUCCI.
BALRAJ SINGH
Connection Strength
9.858
ANTHONY LUCCI
  1. Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer. Cancers (Basel). 2023 Mar 29; 15(7).
    View in: PubMed
    Score: 0.887
  2. Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget. 2022 Nov 17; 13:1272.
    View in: PubMed
    Score: 0.865
  3. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers (Basel). 2022 May 26; 14(11).
    View in: PubMed
    Score: 0.837
  4. Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget. 2021 Mar 30; 12(7):626-637.
    View in: PubMed
    Score: 0.772
  5. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget. 2019 Jun 04; 10(38):3681-3693.
    View in: PubMed
    Score: 0.681
  6. A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget. 2018 Feb 16; 9(13):11071-11082.
    View in: PubMed
    Score: 0.620
  7. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016; 11(7):e0159072.
    View in: PubMed
    Score: 0.557
  8. Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. PLoS One. 2014; 9(10):e109487.
    View in: PubMed
    Score: 0.493
  9. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One. 2012; 7(5):e36510.
    View in: PubMed
    Score: 0.417
  10. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res. 2010 Oct; 163(2):235-43.
    View in: PubMed
    Score: 0.364
  11. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res. 2011 Jun 01; 168(1):e39-49.
    View in: PubMed
    Score: 0.360
  12. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis. 2010 Apr; 27(4):233-40.
    View in: PubMed
    Score: 0.359
  13. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res. 2008 Jun 15; 147(2):240-6.
    View in: PubMed
    Score: 0.313
  14. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res. 2007 Jun 15; 140(2):220-6.
    View in: PubMed
    Score: 0.293
  15. COX-2 involvement in breast cancer metastasis to bone. Oncogene. 2007 May 31; 26(26):3789-96.
    View in: PubMed
    Score: 0.288
  16. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res. 2006 Jul; 134(1):44-51.
    View in: PubMed
    Score: 0.275
  17. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res. 2006 Apr; 131(2):267-75.
    View in: PubMed
    Score: 0.270
  18. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005 May; 26(5):1393-9.
    View in: PubMed
    Score: 0.256
  19. Role of cyclooxygenase-2 in breast cancer. J Surg Res. 2002 Nov; 108(1):173-9.
    View in: PubMed
    Score: 0.216
  20. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. Int J Mol Sci. 2022 Jul 16; 23(14).
    View in: PubMed
    Score: 0.211
  21. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8.
    View in: PubMed
    Score: 0.098
  22. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010 Jul 15; 116(14):3330-7.
    View in: PubMed
    Score: 0.092
  23. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug; 155(2):231-6.
    View in: PubMed
    Score: 0.080
  24. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009 Sep; 117(1):61-8.
    View in: PubMed
    Score: 0.080
  25. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009 Feb; 113(3):501-7.
    View in: PubMed
    Score: 0.078
  26. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther. 2007 Oct; 7(10):1463-72.
    View in: PubMed
    Score: 0.076
  27. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 01; 15(21):6639-48.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.